HighTower Advisors’s Briacell Therapeutics BCTX Stock Holding History

HighTower Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-164	Closed	-$13.9K	–	3765
2024 Q4	$13.9K	Buy	164 +66	+67%	+$7.91K	﹤0.01%	3568
2024 Q3	$18K	Hold	98	–	–	﹤0.01%	3525
2024 Q2	$16K	Buy	98 +2	+2%	+$566	﹤0.01%	3412
2024 Q1	$41K	Sell	96 -10	-9%	-$5.51K	﹤0.01%	3279
2023 Q4	$93K	Hold	106	–	–	﹤0.01%	3214
2023 Q3	$99K	Sell	106 -1	-0.9%	-$979	﹤0.01%	3104
2023 Q2	$104K	Buy	107 +11	+11%	+$10.9K	﹤0.01%	3065
2023 Q1	$107K	Buy	+96	New	+$99.5K	﹤0.01%	2928

Other funds holding BCTX

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CWP

Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HWA

HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

HighTower Advisors's BCTX Position: Q1 2025 in Review

HighTower Advisors sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 164 shares — an estimated $13.9K sold.

HighTower Advisors first reported a position in BCTX in Q1 2023 and held it in 8 quarters. The position peaked at $107K in Q1 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

HighTower Advisors reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
HighTower Advisors sold 164 Briacell Therapeutics shares in Q1 2025, an estimated $13.9K.
HighTower Advisors first reported a position in Briacell Therapeutics in Q1 2023 and held it in 8 quarters.
HighTower Advisors's Briacell Therapeutics position peaked at $107K in Q1 2023.
13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.